Literature DB >> 2201223

Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression.

R F Anton1, E A Burch.   

Abstract

In a double-blind study lasting for 4 weeks, the authors compared the effectiveness of amoxapine, an antidepressant with potential antipsychotic properties, with a combination of amitriptyline plus perphenazine in the treatment of 38 patients who had the diagnosis of major depression with psychotic features (psychotic or delusional depression). Patients in each group showed similar improvement in depression and psychosis. There was a tendency for the patients treated with amitriptyline plus perphenazine to have higher global response rates. However, the patients given amoxapine had significantly fewer extrapyramidal side effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201223     DOI: 10.1176/ajp.147.9.1203

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  15 in total

Review 1.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia.

Authors:  Kevin C Reeves; Subhdeep Virk; Julie Niedermier; Anne-Marie Duchemin
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

3.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

4.  Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.

Authors:  Judith Weissman; Alastair Flint; Barnett Meyers; Samiran Ghosh; Benoit Mulsant; Anthony Rothschild; Ellen Whyte
Journal:  Psychiatry Res       Date:  2012-03-31       Impact factor: 3.222

Review 5.  Evaluation of newer treatment interventions for psychotic depression.

Authors:  B L O'Neal; C L Smith; M Trivedi
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 6.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 7.  Challenges in the treatment of major depressive disorder with psychotic features.

Authors:  Anthony J Rothschild
Journal:  Schizophr Bull       Date:  2013-04-18       Impact factor: 9.306

Review 8.  Metabolism of tricyclic antidepressants.

Authors:  M V Rudorfer; W Z Potter
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 9.  Antipsychotics in older patients. A safety perspective.

Authors:  B G Pollock; B H Mulsant
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

Review 10.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.